Led a $10 million pre-Series A round in US-based biotech company Kure Cells.
Kure Cells is re-engineering the CAR-T manufacturing process to make life-saving cell therapies accessible to every patient, everywhere
Kure Cells is re-engineering the CAR-T manufacturing process to make life-saving cell therapies accessible to every patient, everywhere. Their proprietary Ultra-Fast CAR-T platform reduces manufacturing time to less than 24 hours while preserving T-cell stemness and therapeutic potency.